KRASandBRAFmutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue-Reference-Cited by-同舟云学术

KRASandBRAFmutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue

Published:2013-02-09 Issue:1 Volume:133 Page:130-141
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Mostert Bianca¹,Jiang Yuqiu²,Sieuwerts Anieta M.³,Wang Haiying²,Bolt-de Vries Joan³,Biermann Katharina⁴,Kraan Jaco¹,Lalmahomed Zarina⁵,van Galen Anne³,de Weerd Vanja³,van der Spoel Petra¹,Ramírez-Moreno Raquel⁶,Verhoef Cornelis⁵,IJzermans Jan N.M.⁵,Wang Yixin²,Gratama Jan-Willem¹,Foekens John A.³,Sleijfer Stefan¹,Martens John W.M.³

Affiliation:

1. Department of Medical Oncology; Erasmus University Medical Center; Daniel den Hoed Cancer Center; Rotterdam; The Netherlands

2. Molecular Diagnostics R&D; Veridex LLC; NJ

3. Department of Medical Oncology; Erasmus University Medical Center; Daniel den Hoed Cancer Center and Cancer Genomic Center; Rotterdam; The Netherlands

4. Department of Pathology; Erasmus University Medical Center; Rotterdam; The Netherlands

5. Department of Surgery; Erasmus University Medical Center; Rotterdam; The Netherlands

6. University of Las Palmas de Gran Canaria; Gran Canaria; Spain

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference52 articles.

1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

2. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer;Cutsem;J Clin Oncol,2007

3. Cetuximab for the treatment of colorectal cancer;Jonker;N Engl J Med,2007

4. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers;Barault;Int J Cancer,2008

5. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer;Lievre;Cancer Res,2006

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance of genomic sequencing of circulating tumour cells (CTCs) in cancer;The Journal of Liquid Biopsy;2024-03

2. Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis;Frontiers in Oncology;2023-10-02

3. Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer;Genes;2023-09-16

4. Microfluidics, CTC Capture, Analysis and Expansion;Circulating Tumor Cells;2023

5. Role of Circulating Tumor DNA in Colorectal Cancer;Methods in Molecular Biology;2023